Sibbesen Nina A, Kopp Katharina L, Litvinov Ivan V, Jønson Lars, Willerslev-Olsen Andreas, Fredholm Simon, Petersen David L, Nastasi Claudia, Krejsgaard Thorbjørn, Lindahl Lise M, Gniadecki Robert, Mongan Nigel P, Sasseville Denis, Wasik Mariusz A, Iversen Lars, Bonefeld Charlotte M, Geisler Carsten, Woetmann Anders, Odum Niels
Department of Immunology and Microbiology, University of Copenhagen, Copenhagen, Denmark.
Division of Dermatology, McGill University Health Centre, Montréal, Quebec, Canada.
Oncotarget. 2015 Aug 21;6(24):20555-69. doi: 10.18632/oncotarget.4111.
Aberrant activation of Janus kinase-3 (Jak3) and its key down-stream effectors, Signal Transducer and Activator of Transcription-3 (STAT3) and STAT5, is a key feature of malignant transformation in cutaneous T-cell lymphoma (CTCL). However, it remains only partially understood how Jak3/STAT activation promotes lymphomagenesis. Recently, non-coding microRNAs (miRNAs) have been implicated in the pathogenesis of this malignancy. Here, we show that (i) malignant T cells display a decreased expression of a tumor suppressor miRNA, miR-22, when compared to non-malignant T cells, (ii) STAT5 binds the promoter of the miR-22 host gene, and (iii) inhibition of Jak3, STAT3, and STAT5 triggers increased expression of pri-miR-22 and miR-22. Curcumin, a nutrient with anti-Jak3 activity and histone deacetylase inhibitors (HDACi) also trigger increased expression of pri-miR-22 and miR-22. Transfection of malignant T cells with recombinant miR-22 inhibits the expression of validated miR-22 targets including NCoA1, a transcriptional co-activator in others cancers, as well as HDAC6, MAX, MYCBP, PTEN, and CDK2, which have all been implicated in CTCL pathogenesis. In conclusion, we provide the first evidence that de-regulated Jak3/STAT3/STAT5 signalling in CTCL cells represses the expression of the gene encoding miR-22, a novel tumor suppressor miRNA.
Janus激酶3(Jak3)及其关键下游效应因子信号转导子和转录激活子3(STAT3)以及STAT5的异常激活是皮肤T细胞淋巴瘤(CTCL)恶性转化的关键特征。然而,Jak3/STAT激活如何促进淋巴瘤发生仍仅得到部分理解。最近,非编码微小RNA(miRNA)已被认为与这种恶性肿瘤的发病机制有关。在此,我们表明:(i)与非恶性T细胞相比,恶性T细胞中肿瘤抑制性miRNA miR-22的表达降低;(ii)STAT5结合miR-22宿主基因的启动子;(iii)抑制Jak3、STAT3和STAT5会触发pri-miR-22和miR-22的表达增加。姜黄素,一种具有抗Jak3活性的营养物质和组蛋白去乙酰化酶抑制剂(HDACi)也会触发pri-miR-22和miR-22的表达增加。用重组miR-22转染恶性T细胞可抑制已验证的miR-22靶标的表达,包括其他癌症中的转录共激活因子NCoA1,以及在CTCL发病机制中均有涉及的HDAC6、MAX、MYCBP、PTEN和CDK2。总之,我们提供了首个证据,即CTCL细胞中失调的Jak3/STAT3/STAT5信号传导会抑制编码miR-22(一种新型肿瘤抑制性miRNA)的基因的表达。